bioRxivBiochemistry
Effect of expression of human glucosylceramidase 2 isoforms on lipid profiles in COS-7 cells
P. Jatooratthawichot, C. Talabnin, L. Ngiwsara, Y. H. Rustam, J. Svasti, G. E. Reid, J. R. Ketudat Cairns
Abstract
Glucosylceramide (GlcCer) is a major membrane lipid and the precursor of gangliosides. It is continuously formed and degraded in glycosphingolipid metabolism. GlcCer is mainly degraded by two enzymes, lysosomal acid β-glucosidase (GBA) and nonlysosomal β-glucosidase (GBA2). Deficiencies of GBA and GBA2 affect glycosphingolipid metabolism, resulting in neurological diseases, such as Gaucher Disease and Hereditary Spastic Paraplegia. To understand which GBA2 isoforms are active and how they affect glycosphingolipid levels in cells, we expressed nine human GBA2 isoforms in COS-7 cells, confirmed their expression by qRT-PCR and western blotting, and assayed their activity to hydrolyze 4-methylumbelliferyl-β-D-glucopyranoside (4MUG) in cell extracts. Human GBA2 isoform 1 showed high activity, while the other isoforms had activity similar to the background. Comparison of sphingolipid levels by ultra-high resolution/ accurate mass spectrometry (UHRAMS) analysis showed that isoform 1 overexpression increased ceramide and decreased hexosylceramide levels compared to control and other isoforms. Comparison of ratios of glucosylceramides to the corresponding ceramides in the extracts indicated that GBA2 isoform 1 has broad specificity for the lipid component of glucosylceramide. These studies suggest that only one GBA2 isoform 1 is active and affects sphingolipid levels in the cell, acting on glucosylceramides with a wide range of lipid components. Our study provides new insights into how increased breakdown of GlcCer affects cellular lipid metabolic networks.AbbreviationsCDaseceramidaseCerSceramide synthaseCerceramideCBEConduritol-β-epoxideDAG or DGdiacylglycerolERendoplasmic reticulumGSLglycosphingolipidGBA2glucosylceramidase 2GBAglucosylceramidaseGlcCerglucosylceramideGalCergalactosylceramideHexCerhexosylceramideHexCer(d18: 1/16: 0)hexosylceramide with a C18 sphingosine (d18: 1) and N-acyl group (16: 0)MGmonoacylglycerolLPCLysophosphatidylcholineLPELysophosphatidylethanolaminePAPhosphatidic acidPCphosphatidylcholinePEphosphatidylethanolaminePGPhosphatidylglycerolPIphosphatidylinositolPSphosphatidylserineSLsphingolipidSMsphingomyelinSMasesphingomyelinaseSMSsphingomyelin synthaseSphsphingosineSPTserine palmitoyltransferaseS1Psphingosine-1-phosphate4MUG4-Methylumbelliferyl-β-D-glucopyranosideTGtriacylglycerolView Full Text
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Glucosylceramide synthase is required for C6-ceramide nanoliposome-induced organelle stress and cell death
Luke R. Vass, Ella Weber Smith, … Todd E. Fox·bioRxiv·Sep 22, 2026
- A glucosylcholesterol-cytoskeleton axis links GBA2 loss-of-function to synaptic and mitochondrial pathology in Hereditary Spastic Paraplegia
Angelica Casotto, Chiara Sinisgalli, … Nicoletta Plotegher·bioRxiv·Aug 31, 2026
- The mechanism of sphingolipid processing revealed by a GALC-SapA complex structure
Chris H. Hill, Georgia M. Cook, … Janet Elwyn Deane·Nature CommunicationsPeer-reviewed·Jan 5, 2018
- Glucosylceramide depletion disrupts endolysosomal function in GBA-linked Parkinsons fibroblasts?
M. Bhardwaj, Z. Kula, … D. J. Sillence·bioRxiv·Nov 30, 2023
- Restoration of beta-GC trafficking improves the lysosome function in Gaucher disease
S. Patel, D. Radhakrishnan, … S. R. G. Setty·bioRxiv·Jun 23, 2022
- Glucocerebrosidase Deficiency Dysregulates Human Astrocyte Lipid Metabolism
Aboud Tahanis, Thao Nguyen, … Robert Krencik·bioRxiv·Jan 9, 2025